A clinical study showed that the use of Anti-IL-17A monoclonal antibodies or inhibition of the Th17/Tc17 axis could alleviate lesions in patients (143), which indicated that IL-17 is a potential entry point for OLP treatment. This evidence concerns the gene IL17A and oral lichen planus.